New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib

Yulong Zheng, Weijia Fang, Xiao Liu, and Nong Xu

Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

ABSTRACT

Icotinib is a new oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We report on a 49-year-old man with recurrent lung adenocarcinoma treated with icotinib. The patient obtained a partial remission in 4 weeks that was maintained 14 months. Retrospective examination of EGFR mutations confirmed he had a sensitive mutation (exon 19 deletion). This case supports that icotinib has great efficacy in advanced non-small cell lung cancer with sensitive EGFR mutations.

Key words: non-small cell lung cancer, epidermal growth factor, tyrosine kinase inhibitor, mutation.

Conflict of interest statement: The authors declared no conflicts of interest.

Correspondence to: Nong Xu, Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003, China.
Tel +86-571-56731277; fax +86-571-56731277; email xunong126@126.com

Received August 18, 2011; accepted October 11, 2011.